Stockreport

Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting [Yahoo! Finance]

IceCure Medical Ltd. - Ordinary Shares  (ICCM) 
PDF FDA Advisory Panel voted in favor of IceCure's ProSense® cryoablation benefit-risk profile in early-stage low risk breast cancer in Nov. 2025 FDA's marketing authoriz [Read more]